CRISPR Therapeutics AG (CRSP) Cash & Equivalents (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash & Equivalents across 12 years of filings, most recently posting $291.3 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 50.47% year-over-year to $291.3 million; the TTM figure through Jun 2026 stood at $291.3 million (up 50.47% YoY), while the FY2025 annual figure was $347.6 million, up 16.51% from the prior year.
• Cash & Equivalents came in at $291.3 million for Q2 2026 at CRISPR Therapeutics AG, down from $423.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $707.4 million in Q1 2024 to a low of $193.6 million in Q2 2025.
• Average Cash & Equivalents over 5 years is $393.7 million, with a median of $368.5 million recorded in 2023.
• Year-over-year, Cash & Equivalents sank 77.04% in 2022 and surged 105.4% in 2024.
• Over 5 years, Cash & Equivalents stood at $211.9 million in 2022, then soared by 83.82% to $389.5 million in 2023, then retreated by 23.41% to $298.3 million in 2024, then advanced by 16.51% to $347.6 million in 2025, then retreated by 16.18% to $291.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $291.3 million in Q2 2026, $423.3 million in Q1 2026, and $347.6 million in Q4 2025.